Streetbeat News

Products Services

AZN

EWJ

AstraZeneca's Truqap, in combination with Faslodex, has been approved in Japan for treating advanced HR-positive, HER2-negative breast cancer. The approval is based on the CAPItello-291 study results, which demonstrated a 50% reduction in the risk of disease progression or death compared to Faslodex alone.

Portfolio Pulse from Charles Gross

March 27, 2024 | 8:56 am

HYMTF

Kia Corporation, an affiliate of Hyundai Motor (OTCPK: HYMTF), has appointed renowned auto designers Oliver Samson and Seungmo Lim as Senior Chief Designers for its Europe and China Design Centers, respectively. Both designers have extensive experience with leading automakers, including Mercedes, Geely, Nio Inc, Changan Automobile, and BMW. Their recruitment is part of Kia's strategy to elevate its electric vehicle (EV) design, focusing on the development of smaller, more affordable EVs like the EV5, EV4, and EV3, priced between $35,000 and $50,000.

Portfolio Pulse from Anan Ashraf

March 27, 2024 | 8:49 am

RXT

Rackspace has introduced Digital Sovereignty Solutions aimed at the UK government and regulated industries like healthcare, law enforcement, pharma, and financial services. These solutions ensure data, support, and infrastructure remain within the UK, aiding regulatory compliance and reducing security risks amid rising global cyberthreats.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:21 am

CTSH

Cognizant has renewed its collaboration with Pon IT to continue providing managed services for cloud platforms, aiming to enhance agility, intuition, and innovation for Pon IT and its operating companies.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:06 am

VFS

Marques Brownlee, known as MKBHD, reviewed VinFast Auto's VF8, noting its similarities to the Fisker Ocean SUV, which he previously criticized. Despite some changes in materials and design to cut costs, Brownlee found the VF8's quality lacking, with issues like poor vegan leather seats, an outdated center screen, and a low-quality reverse camera. He concluded that the VF8, priced around $50,000, is a poor choice compared to other SUVs in the same price range. VinFast shares closed down 2.69% at $4.7, marking a 33.33% decline year-to-date.

Portfolio Pulse from Anan Ashraf

March 27, 2024 | 7:46 am

TSLA

Canaccord Genuity analyst George Gianarikas reaffirmed a bullish stance on Tesla, Inc. (NASDAQ:TSLA), despite prevailing negativity. He attributes recent delivery shortfalls to supply constraints, not demand issues, and anticipates positive earnings revisions in 2024 due to potential margin expansion and Cybertruck production ramp-up. Gianarikas revised his delivery and earnings estimates for Tesla and highlighted the company's strategy of offering software upgradable vehicles with high-margin software as a catalyst for future growth. He maintained a Buy rating and $234 price target for Tesla.

Portfolio Pulse from Shanthi Rexaline

March 27, 2024 | 7:32 am

HON

Honeywell is set to acquire Civitanavi Systems for €200M, aiming to enhance its aerospace autonomy capabilities and expand its presence in Europe. Civitanavi's expertise in high-precision inertial navigation and stabilization solutions is expected to drive long-term growth in Honeywell's commercial and defense sectors. The integration of technologies from both companies will offer new opportunities for autonomous operations in these areas.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 7:12 am

ARGX

argenx has announced its decision to continue the development of Efgartigimod for the treatment of primary Sjogren's disease, based on positive results from the RHO study. The decision was influenced by the drug's favorable safety profile and consistent efficacy and biomarker measures.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 7:06 am

AMZN

EL

Clinique, a subsidiary of Estee Lauder Companies Inc. (EL), has expanded its US market presence by launching its products in Amazon's Premium Beauty Store. This move aims to leverage Amazon's vast customer base and distribution network to increase Clinique's product accessibility and sales.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 7:04 am

GCTS

GCT and Concord Acquisition have completed their merger, launching GCT on the NYSE under the ticker 'GCTS' with a pro-forma valuation of approximately $667 million. The transaction provided GCT with around $50 million in gross proceeds to support the development of a 5G chipset portfolio and expansion into new markets. Approximately $49 million was raised through PIPE and convertible note financing from existing and new investors. Existing GCT stockholders retained their equity, and most outstanding convertible notes will convert to common stock.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 7:00 am